Related references
Note: Only part of the references are listed.Purified and highly aggregated chimeric protein DIIIC-2 induces a functional immune response in mice against dengue 2 virus
Ernesto Marcos et al.
ARCHIVES OF VIROLOGY (2013)
An Alphavirus Vector-Based Tetravalent Dengue Vaccine Induces a Rapid and Protective Immune Response in Macaques That Differs Qualitatively from Immunity Induced by Live Virus Infection
Laura J. White et al.
JOURNAL OF VIROLOGY (2013)
Efficacy of tetravalent dengue vaccine in Thai schoolchildren
Meng Ling Moi et al.
LANCET (2013)
Serotype specificity of recombinant fusion protein containing domain III and capsid protein of dengue virus 2
Alienys Izquierdo et al.
ANTIVIRAL RESEARCH (2012)
Recombinant nucleocapsid-like particles from dengue-2 induce functional serotype-specific cell-mediated immunity in mice
Lazaro Gil et al.
JOURNAL OF GENERAL VIROLOGY (2012)
Recombinant Dengue Type 2 Viruses with Altered E Protein Domain III Epitopes Are Efficiently Neutralized by Human Immune Sera
Wahala M. P. B. Wahala et al.
JOURNAL OF VIROLOGY (2012)
Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial
Arunee Sabchareon et al.
LANCET (2012)
Antibodies targeting dengue virus envelope domain III are not required for serotype-specific protection or prevention of enhancement in vivo
Katherine L. Williams et al.
VIROLOGY (2012)
The Chimeric Protein Domain III-Capsid of Dengue Virus Serotype 2 (DEN-2) Successfully Boosts Neutralizing Antibodies Generated in Monkeys upon Infection with DEN-2
Iris Valdes et al.
CLINICAL AND VACCINE IMMUNOLOGY (2011)
Intracellular Cytokine Production by Dengue Virus-specific T cells Correlates with Subclinical Secondary Infection
Steven Hatch et al.
JOURNAL OF INFECTIOUS DISEASES (2011)
An In-Depth Analysis of Original Antigenic Sin in Dengue Virus Infection
Claire M. Midgley et al.
JOURNAL OF VIROLOGY (2011)
The two component adjuvant IC31® potentiates the protective immunity induced by a dengue 2 recombinant fusion protein in mice
Lidice Bernardo et al.
VACCINE (2011)
A human challenge model for dengue infection reveals a possible protective role for sustained interferon gamma levels during the acute phase of illness
V. J. Gunther et al.
VACCINE (2011)
Update on the global spread of dengue
Alfonso Guzman et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2010)
Heterologous prime-boost strategy in non-human primates combining the infective dengue virus and a recombinant protein in a formulation suitable for human use
Iris Valdes et al.
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES (2010)
A Novel Tetravalent Dengue Vaccine Is Well Tolerated and Immunogenic against All 4 Serotypes in Flavivirus-Naive Adults
Dennis Morrison et al.
JOURNAL OF INFECTIOUS DISEASES (2010)
Development of a recombinant tetravalent dengue virus vaccine: Innmunogenicity and efficacy studies in mice and monkeys
David E. Clements et al.
VACCINE (2010)
Protection against dengue virus by non-replicating and live attenuated vaccines used together in a prime boost vaccination strategy
Monika Simmons et al.
VIROLOGY (2010)
In vitro assembly of nucleocapsid-like particles from purified recombinant capsid protein of dengue-2 virus
Carlos Lopez et al.
ARCHIVES OF VIROLOGY (2009)
Antibodies Induced by Dengue Virus Type 1 and 2 Envelope Domain III Recombinant Proteins in Monkeys Neutralize Strains with Different Genotypes
Lidice Bernardo et al.
CLINICAL AND VACCINE IMMUNOLOGY (2009)
Immunological evaluation in nonhuman primates of formulations based on the chimeric protein P64k-domain III of dengue 2 and two components of Neisseria meningitidis
Iris Valdes et al.
VACCINE (2009)
The Cellular Immune Response Plays an Important Role in Protecting Against Dengue Virus in the Mouse Encephalitis Model
Lazaro Gil et al.
VIRAL IMMUNOLOGY (2009)
A novel fusion protein domain III-capsid from dengue-2, in a highly aggregated form, induces a functional immune response and protection in mice
Iris Valdes et al.
VIROLOGY (2009)
Dengue virus neutralization by human immune sera: Role of envelope protein domain III-reactive antibody
W. M. P. B. Wahala et al.
VIROLOGY (2009)
Immunogenicity and protective efficacy of a recombinant fusion protein containing the domain III of the dengue 1 envelope protein in non-human primates
Lidice Bernard et al.
ANTIVIRAL RESEARCH (2008)
A Complex Interplay among Virus, Dendritic Cells, T Cells, and Cytokines in Dengue Virus Infections
Wanwisa Dejnirattisai et al.
JOURNAL OF IMMUNOLOGY (2008)
Primary and secondary infections of Macaca fascicularis monkeys with Asian and American genotypes of dengue virus 2
Lidice Bernardo et al.
CLINICAL AND VACCINE IMMUNOLOGY (2008)
CpG oligodeoxynucleotides as DNA adjuvants in vertebrates and their applications in immunotherapy
Hso-Chi Chaung
INTERNATIONAL IMMUNOPHARMACOLOGY (2006)
A recombinant fusion protein containing the domain III of the dengue-2 envelope protein is immunogenic and protective in nonhuman primates
L Hermida et al.
VACCINE (2006)
An evaluation of dengue type-2 inactivated, recombinant subunit, and live-attenuated vaccine candidates in the rhesus macaque model
JR Putnak et al.
VACCINE (2005)
Safety and efficacy of chimeric yellow fever-dengue virus tetravalent vaccine formulations in nonhuman primates
F Guirakhoo et al.
JOURNAL OF VIROLOGY (2004)
Interferon-dependent immunity is essential for resistance to primary dengue virus infection in mice, Whereas T- and B-cell-dependent immunity are less critical
S Shresta et al.
JOURNAL OF VIROLOGY (2004)
Viremia and immunogenicity in nonhuman primates of a tetravalent yellow fever-dengue chimeric vaccine: Genetic reconstructions, dose adjustment, and antibody responses against wild-type dengue virus isolates
F Guirakhoo et al.
VIROLOGY (2002)
Human peripheral blood cells differentially recognize and respond to two distinct CpG motifs
D Verthelyi et al.
JOURNAL OF IMMUNOLOGY (2001)
Share Paper
